XML 26 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-Based Compensation
3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation

Note 10. Stock-Based Compensation

Total estimated stock-based compensation expense for employees and non-employees, related to all of the Company’s stock-based awards, was as follows:

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2024

 

 

2023

 

 

 

(in thousands)

 

Cost of revenue

 

$

131

 

 

$

175

 

Selling and marketing

 

 

487

 

 

 

490

 

Research and development

 

 

224

 

 

 

356

 

General and administrative

 

 

263

 

 

 

938

 

Total stock-based compensation

 

$

1,105

 

 

$

1,959

 

 

The following table presents the stock activity and the total number of shares available for grant as of March 31, 2024:

 

 

 

(in thousands)

 

Balance at December 31, 2023

 

 

1,059

 

Restricted Stock Granted

 

 

(2

)

Restricted Stock Forfeited

 

 

14

 

Balance at March 31, 2024

 

 

1,071

 

 

Stock Option Activity

 

 

 

Options Outstanding

 

 

 

Number of
Shares
Underlying
Outstanding
Options

 

 

Weighted-
Average
Exercise
Price

 

 

Weighted-
Average
Remaining
Contractual
Term

 

 

Aggregate
Intrinsic
Value

 

 

 

 

 

 

 

 

 

(in years)

 

 

 

 

Outstanding at December 31, 2023

 

 

1,041,452

 

 

$

9.10

 

 

 

4.22

 

 

$

3,137,285

 

Options Granted

 

 

-

 

 

 

-

 

 

 

 

 

 

 

Options Exercised

 

 

(170,919

)

 

 

7.81

 

 

 

 

 

 

 

Options Forfeited

 

 

(824

)

 

 

60.87

 

 

 

 

 

 

 

Outstanding at March 31, 2024

 

 

869,709

 

 

$

9.30

 

 

 

4.45

 

 

$

7,234,873

 

Vested and expected to vest at March 31, 2024

 

 

871,245

 

 

$

9.53

 

 

 

4.45

 

 

$

7,234,613

 

Exercisable at March 31, 2024

 

 

848,910

 

 

$

9.50

 

 

 

4.41

 

 

$

7,077,588

 

 

Stock options are time-based and the majority are exercisable within 10 years of the date of grant, but only to the extent they have vested. The options generally vest as specified in the option agreements subject to acceleration in certain circumstances. In the event participants in the plan cease to be employed or engaged by the Company, all vested options would be forfeited if they are not exercised within 90 days. Forfeitures on option grants are estimated at 10% for non-executives and 0% for executives based on evaluation of historical and expected future turnover. Stock-based compensation expense was recorded net of estimated forfeitures, such that expense was recorded only for those stock-based awards expected to vest. The Company reviews this assumption periodically and will adjust it if it is not representative of future forfeiture data and trends within employee types (executive vs. non-executive).

Aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock and the exercise price of outstanding, in-the-money options. The aggregate intrinsic value of options exercised was $1.2 million for the three months ended March 31, 2024.

 

The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted as of the grant date. There were no new options granted during the three months ended March 31, 2024. The total estimated fair value of employee options vested during the three months ended March 31, 2024 was $1.1 million. As of March 31, 2024, total unrecognized compensation cost related to non-vested stock options granted to employees was $0.1 million, which is expected to be recognized over a remaining weighted average vesting period of 0.3 years.

Restricted Stock Activity

 

 

 

Shares

 

 

Weighted
Average
Grant Date
Fair Value
Per Share

 

Nonvested restricted stock at December 31, 2023

 

 

764,942

 

 

$

14.76

 

Granted

 

 

1,850

 

 

 

12.12

 

Vested

 

 

(12,066

)

 

 

21.24

 

Shares forfeited

 

 

(13,935

)

 

 

9.10

 

Nonvested restricted stock at March 31, 2024

 

 

740,791

 

 

$

14.75

 

 

As of March 31, 2024, total unrecognized compensation costs related to the nonvested restricted stock awards was $7.0 million, which will be recognized over a remaining weighted average vesting period of 3.4 years.

Performance-Based Restricted Share Units

 

As of March 31, 2024, the Company had 162,672 performance-based restricted share units outstanding. The vesting of performance-based restricted share units is determined over a three-year period based on (i) the amount by which revenue growth exceeds a defined baseline market growth each year and (ii) the achievement of specified tiers of adjusted EBITDA as a percentage of net revenue each year, with the ability to earn and vest into such units ranging from 0% to 200%. As of March 31, 2024, achievement of the performance conditions associated with the 2023, 2022 and 2021 performance shares was deemed not probable.